(12) Patent Application Publication (10) Pub. No.: US 2016/0237398 A1 Kalyuzhnaya Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 2016O237398A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0237398 A1 Kalyuzhnaya et al. (43) Pub. Date: Aug. 18, 2016 (54) METHODS OF MICROBIAL PRODUCTION (86). PCT No.: PCT/US1.4f61304 OF EXCRETED PRODUCTS FROM S371 (c)(1) METHANE AND RELATED BACTERIAL (2) Date: Apr. 15, 2016 STRANS Related U.S. Application Data (71) Applicant: UNIVERSITY OF WASHINGTON THROUGHTS CENTERFOR (60) Eyal application No. 61/892,909, filed on Oct. COMMERCIALIZATION, Seattle, s WA (US) Publication Classification (72) Inventors: Marina Kalyuzhnaya, Seattle, WA (51) Int. Cl. (US); Mary E. Lidstrom, Seattle, WA CI2N I/20 (2006.01) (US) CI2P 7/02 (2006.01) CI2P 7/40 (2006.01) (52) U.S. Cl. (73) Assignee: UNIVERSITY OF WASHINGTON CPC. CI2N 1/20 (2013.01); C12P 7/40 (2013.01); THROUGHTS CENTERFOR CI2P 7/02 (2013.01) COMMERCIALIZATION, Seattle, WA (US) (57) ABSTRACT The present disclosure is directed to methods of producing (21) Appl. No.: 15/029,968 excreted products through the fermentation of methane with methanotrophs. In certain embodiments, the methods are per (22) PCT Fled: Oct. 20, 2014 formed at low oxygen levels. Patent Application Publication Aug. 18, 2016 Sheet 1 of 16 US 2016/0237398 A1 ########~## 3#######~## {######################$$$ ########## #######~###3 ######### ("~~~~q)+":"~~~~q) ####§§§ VI"OI) sess ex www.ww.wn M w.rwise-- s - 8 s es se Patent Application Publication Aug. 18, 2016 Sheet 2 of 16 US 2016/0237398 A1 i s w s s as: s s vex &x s iii) Patent Application Publication Aug. 18, 2016 Sheet 3 of 16 US 2016/0237398 A1 -- ... -- E --3 2 - S-- FF/EP -- E(R) i-- R-. -- -- Patent Application Publication Aug. 18, 2016 Sheet 4 of 16 US 2016/0237398 A1 -- -- B-2 2PG/3PG --3 s 8 68 s 4e Bi-- S. -- PRA E-3 s E. 66 s e 46 e FIG. 3 (cont.) Patent Application Publication Aug. 18, 2016 Sheet 5 of 16 US 2016/0237398 A1 is as is as social acao 8 S SS - - - & a is is is 8 s se sex s se s es ses Patent Application Publication Aug. 18, 2016 Sheet 6 of 16 US 2016/0237398 A1 Patent Application Publication Aug. 18, 2016 Sheet 11 of 16 US 2016/0237398 A1 ATGTCAATG-CAA CAGAATGAGCCA GTTC CATTAAATGAGCCACTTCA GGGTTAGAGCTTGAAGCTGATTGAGTCGAAATCCCCCCA (CATAAAAA GTTGAAAGGATGAGCGGTGACGATG-G-GTACGGCGA CGTCAT.G.A.A.A.A.A.A.G. GCECTAGGAAAACAGGGGAA CAAATTCAA CTCCACATA GGAAGAAATCAA TAAGAAATGTTGATSTCGATAGCCTCGGCTCGCCTTAGCCAGCTGAATCTACTAT GATGCCCAA GAAGCCGTA CAATGAGTGATCCA:CGAAA GCACAATTCCCGACCA AGTCGAACTGGGCGAACTATAAACGCTGGAATGGCCGTCCACCGCA CGCACCATGCCCAAAAAAGCCCCGCGCGGTGCGGGCATCCCAGA GATCAT AAAGCACTTAAAAAGCT(CCCA GT AATTACA FIG. 8 (cont.) Patent Application Publication Aug. 18, 2016 Sheet 13 of 16 US 2016/0237398 A1 G{CAA CCCACCACGAAGATGACAAACACAGGACGCACCCCGGC "ACA"TCOGCAC GCACACCGGAA. ACGCCGCA, CGGCAGCGAAGAC AACGAA CAATG{CCGCACGTCGGCTCACATCCC{CAA CTAG CAAC AGATTAGEAAACA, CGAAAAACARACCCCAAAAAACA: OCAAATC CTCCAAGGCAA CATTT GCCCCCGC AAAAATCCGGGAAC (CCAAACAAG GCCAA. A GAAA CGA CAAA (CECAFAC CGGAAGAAAAG CAT CACCACCGGACGTCATGACGACCAAATCCT CATTTGCACC ATCC AGCCAC, CCAACAA{{CCA, CGCTAAA (ACG (CGATTCAGGCCCCCAAA AAGCATCATCGTAATCCGA.GTCCGGGCAGTAAAAGACAGCGATATCACCCACCG ACCGA (CCGCACACCACC FIG. 9 (cont.) US 2016/0237398 A1 Aug. 18, 2016 METHODS OF MICROBAL PRODUCTION for single carbon (C1)-assimilation 12-14. The major bio OF EXCRETED PRODUCTS FROM chemical evidence that favored the EDD variant of the RuMP METHANE AND RELATED BACTERIAL cycle included relatively high activities of two key enzymes STRANS of the pathway (6-phosphogluconate dehydratase and 2-keto 3-deoxy-6-phosphogluconate aldolase) and multiple enzy CROSS-REFERENCE TO RELATED matic lesions in the Embden-Meyerhof-Parnas (EMP) path APPLICATIONS way 15-16. Activity of pyruvate kinase has not been detected previously in any gammaproteobacterial methan 0001. This application claims benefit under 35 U.S.C. otrophs 16-17. The presence of a reversible pyrophosphate S119(e) of U.S. Provisional Application No. 61/892,909 filed (PPi)-dependent phosphofructotransferase led to the conclu Oct. 18, 2013, the contents of which are incorporated herein sion that the EMP pathway represents a metabolic loop bal by reference in their entirety. ancing the level of glyceraldehyde-3-phosphate (GAP) and GOVERNMENT SUPPORT phosphoenolpyruvate (PEP) 16,18). This metabolic arrange ment has served as the foundation for theoretical character 0002 This invention was made with federal funding under ization of efficiency and yield of methane utilization 14-15. Grant Nos. MCB-0842686, awarded by the National Science However, the predicted maximum carbon conversion effi Foundation, and under DE-SC0005154, awarded by the ciency (39-47%) was considerably less than measured values Department of Energy. The U.S. government has certain (64-66.5%) 15, 19. rights in the invention. SUMMARY SEQUENCE LISTING 0008. The technology described herein is directed to 0003. The instant application contains a Sequence Listing methods and compositions relating to the fermentation of which has been submitted electronically in ASCII format and methane by methantrophic microorganisms, e.g., for the pro is hereby incorporated by reference in its entirety. Said ASCII duction of execreted products (e.g. organic acids and/or alco copy, created on Oct. 16, 2014, is named 034186-082620 hols). PCT SL.txt and is 30,731 bytes in size. 0009. In this work, multi-pronged systems-level approaches were used to reassess the metabolic functions for TECHNICAL FIELD methane utilization in a promising bacterial biocatalyst. We demonstrate that methane assimilation is coupled with a 0004. The technology described herein relates to the highly efficient pyrophosphate-mediated glycolytic pathway, microbial conversion of methane to, e.g., organic acids and/or which under O limitation participates in a novel form of alcohols. fermentation-based methanotrophy. This Surprising discov ery suggests a novel mode of methane utilization in O-lim BACKGROUND ited environments, and opens new opportunities for a modular 0005 Methane is an essential component of the global approach towards producing a variety of excreted chemical carbon cycle and one of the most powerful greenhouse gases, products using methane as a feedstock. yet it is also one of the most promising alternative sources of 0010. In one aspect, described herein is a method for pro carbon for biological production of chemicals of high added ducing at least one excreted product by microbial fermenta value. Aerobic methane-consuming bacteria (methanotro tion of a gaseous Substrate, comprising: (a) providing a gas phs) represent a potential biological platform for methane eous Substrate comprising CH4 and optionally, O, to a based biocatalysis. culture of at least one methanotrophic microorganism; and (b) 0006 Nature provides two alternative forms of methane as maintaining the microorganism under conditions suitable for a resource: natural gas, relatively abundant today but still a fermentationata dissolved O tension of between 0 and about nonrenewable fossil fuel, and renewable bio-gas, a byproduct 1% of saturation with air to produce at least one excreted of modern society that is often wasted 1-3. Interest in new product; or maintaining the microorganism under conditions technologies for effective conversion of flared/wasted suitable for fermentationata dissolved O, tension of between Sources of methane into chemical compounds, including 0 and about 40% of saturation with air and reducing respira next-generation fuels, continues to increase 4-6. The use of tion to produce at least one excreted product. In some microbial cells and enzymes as catalysts for methane conver embodiments, the methanotrophic microorganism can be a sion represents an appealing approach in this context 7-11. native methanotrophic microorganism. In some embodi The benefits of methane biotechnology include a self-sustain ments, reducing respiration can comprise contacting the able component, since any biomass generated could be used microorganism with an inhibitor of the electron transport as single cell protein or converted back to methane via anaero chain. In some embodiments, the inhibitor is antimycin A. bic digestion. However, besides single cell protein and poly 0011. In some embodiments, the methanotrophic micro hydroxybutyrate, exploitation of methane-based catalysis for organism can be engineered to comprise a downregulated the production of chemicals and fuels has not yet proven level of a gene selected from the group consisting of NAD Successful at the commercial level. reducing hydrogenase (MALCv4 1304 and 1307); acetate 0007 Gammaproteobacterial methanotrophs with the kinase (MALCv4 2853); lactate dehydrogenase (MALCV4 ribulose monophosphate (RuMP) pathway are among the 0534); acetate kinase (MALCV4 2853) and lactate dehydro most promising microbial systems for methane-based bio genase (MALCV4 0534); bacteriohemerythrin (MALCV4 technology. Reconstruction of the methane utilization net 2316); sucrose-phosphate synthase (MALCv4 0614); and work in these methanotrophs has been based on a number of sucrose-phosphate synthase (MALCV4 0614) and bacterio biochemical studies that pointed toward the Entner-Doudor hemerythrin (MALCV4 2316); a member of the cytochrome off (EDD)-variant of the RuMP pathway as the major route be complex (MALCv4 0634, MALCv4 0633, and US 2016/0237398 A1 Aug. 18, 2016 MALCV4 0632); a glycogen biosynthesis gene (MALCV4 for fermentation at a dissolved O tension of between 0 and 3502: MALCv4 3503; MALCv 3504: MALCv4 3505; about 40% of saturation with air to produce at least one MALCv 3506; MALCv4 3507,